Business
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain. “We are pleased to pr
About this update from Assembly Biosciences, Inc.
[{"type":"image","alt":"Assembly Biosciences, Inc.","displaySize":"","headline":null,"caption":"Assembly Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MDnne0t7yPjd24iiqZ4Sig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8","width":300,"height":62},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MDnne0t7yPjd24iiqZ4Sig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8","width":300,"height":62}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain.","length":478,"tagName":"p"},{"type":"text","content":"“We are pleased to present additional Phase 1a data on ABI-6250 at EASL,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “As the only oral entry inhibitor currently in clinical development for chronic hepatitis D, ABI-6250 is designed to offer a differentiated approach, and these data further support our plan to advance directly into a Phase 2 study by year-end.”","length":384,"tagName":"p"},{"type":"text","content":"The presentation will feature results from a randomized, blinded, Phase 1a study evaluating the safety, pharmacokinetics and pharmacodynamic activity of ABI-6250 following single- and multiple-dose administration in healthy participants.","length":237,"tagName":"p"},{"type":"text","content":"Presentation details are as follows:","length":36,"tagName":"p"},{"type":"text","content":"Title: Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor, in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a StudyPresenter: Edward J. Gane, ...